Alzheimer’s Transition from Asymptomatic to Dementia May Be Foreseen in a Protein Biomarker

Alzheimer’s Transition from Asymptomatic to Dementia May Be Foreseen in a Protein Biomarker
Researchers in Germany have identified a potential brain inflammation biomarker in the cerebrospinal fluid of patients with early and asymptomatic Alzheimer’s disease. This biomarker may help clinicians identify Alzheimer's at its transition stage from preclinical disease to cognitive impairment and dementia progression. The research, titled “sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers,” was published in EMBO Molecular Medicine. Two of Alzheimer’s disease (AD) hallmarks, amyloid peptide plaques and tau protein aggreagates, are often used as preclinical diagnostic markers. However, the diagnostic measure of these structures in the cerebrospinal fluid has low specificity, because an individual can present these anomalies but maintain cognitive abilities for several years post-diagnosis. Early and accurate diagnosis of AD could increase treatment options for patients and facilitate clinical trials of new therapeutic agents, so research greatly focuses on the discovery of early disease biomarkers. In previous studies, researchers have shown that the loss of the function of the protein TREM2, an innate immune receptor expressed on the surface of microglia, impairs the defense abilities of microglial cells, reducing the clearance of amyloid plaques. Such observations have led researchers to believe that TREM2 may play an important role in the pathogenesis of AD and the onset of neurodegeneration. Researchers in this multicenter study focused on the TREM-2 protein and its ro
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *